Literature DB >> 27498610

Population structure of invasive Streptococcus pneumoniae isolates among Alaskan children in the conjugate vaccine era, 2001 to 2013.

Karen M Miernyk1, Lisa R Bulkow2, Samantha L Case2, Tammy Zulz2, Michael G Bruce2, Marcella Harker-Jones2, Debby A Hurlburt2, Thomas W Hennessy2, Karen M Rudolph2.   

Abstract

Here we describe the relationships between serotypes, genotypes, and antimicrobial susceptibility among isolates causing invasive pneumococcal disease in Alaskan children during the pneumococcal conjugate vaccine (PCV) era. From 2001 to 2013 we received 271 isolates representing 33 serotypes. The most common serotypes were 19A (29.5%, n= 80), 7F (12.5%, n= 34), 15B/C (6.3%, n= 17), and 22F (4.8%, n= 13). Multilocus sequence typing identified 11 clonal complexes (CC) and 45 singletons. Five CCs accounted for 52% (141/271) of the total: CC199 (21% [n= 57], serotypes 19A, 15B/C), CC191 (12.2% [n= 33], serotype 7F), CC172 (10.3% [n= 28], serotypes 19A, 23A, 23B), CC433 (4.4% [n= 12], serotype 22F), and CC100 (4.4% [n= 12], serotype 33F). The proportion of isolates nonsusceptible to erythromycin and tetracycline increased after 13-valent PCV use (14% [n= 30] versus 29% [n= 14]; P= 0.010) and (4% [n= 9] versus 22% [n= 11]; P< 0.001), respectively. The genetic diversity also increased after 13-valent PCV use (Simpson's diversity index =0.95 versus 0.91; P= 0.022). Published by Elsevier Inc.

Entities:  

Keywords:  Antimicrobial susceptibility; Molecular epidemiology; Multilocus sequence typing; Pneumococcal conjugate vaccines; Serotypes; Streptococcus pneumoniae

Mesh:

Substances:

Year:  2016        PMID: 27498610      PMCID: PMC5649341          DOI: 10.1016/j.diagmicrobio.2016.07.004

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  33 in total

1.  Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era.

Authors:  Robert E Gertz; Zhongya Li; Fabiana C Pimenta; Delois Jackson; Billie A Juni; Ruth Lynfield; James H Jorgensen; Maria da Gloria Carvalho; Bernard W Beall
Journal:  J Infect Dis       Date:  2010-03       Impact factor: 5.226

2.  Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Authors:  Anneke Steens; Marianne A Riise Bergsaker; Ingeborg S Aaberge; Karin Rønning; Didrik F Vestrheim
Journal:  Vaccine       Date:  2013-10-29       Impact factor: 3.641

3.  Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine.

Authors:  Rodrigo E Mendes; Andrew J Costello; Michael R Jacobs; Donald Biek; Ian A Critchley; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2014-05-24       Impact factor: 2.803

4.  Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.

Authors:  Walter H B Demczuk; Irene Martin; Averil Griffith; Brigitte Lefebvre; Allison McGeer; Marguerite Lovgren; Gregory J Tyrrell; Shalini Desai; Lindsey Sherrard; Heather Adam; Matthew Gilmour; George G Zhanel
Journal:  Can J Microbiol       Date:  2013-10-21       Impact factor: 2.419

5.  Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.

Authors:  Pauline A Waight; Nicholas J Andrews; Shamez N Ladhani; Carmen L Sheppard; Mary P E Slack; Elizabeth Miller
Journal:  Lancet Infect Dis       Date:  2015-03-20       Impact factor: 25.071

6.  Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.

Authors:  Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Catherine Lexau; Nancy M Bennett; Susan Petit; Shelley M Zansky; Lee H Harrison; Arthur Reingold; Lisa Miller; Karen Scherzinger; Ann Thomas; Monica M Farley; Elizabeth R Zell; Thomas H Taylor; Tracy Pondo; Loren Rodgers; Lesley McGee; Bernard Beall; James H Jorgensen; Cynthia G Whitney
Journal:  Lancet Infect Dis       Date:  2015-02-03       Impact factor: 25.071

7.  Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.

Authors:  Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson
Journal:  JAMA       Date:  2007-04-25       Impact factor: 56.272

8.  The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial.

Authors:  Rosalyn Singleton; Jay Wenger; Joseph A Klejka; Lisa R Bulkow; Allison Thompson; Denise Sarkozy; Emilio A Emini; William C Gruber; Daniel A Scott
Journal:  Pediatr Infect Dis J       Date:  2013-03       Impact factor: 2.129

9.  Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska.

Authors:  Michael G Bruce; Rosalyn Singleton; Lisa Bulkow; Karen Rudolph; Tammy Zulz; Prabhu Gounder; Debby Hurlburt; Dana Bruden; Thomas Hennessy
Journal:  Vaccine       Date:  2015-08-04       Impact factor: 3.641

10.  Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era.

Authors:  Mark van der Linden; Stephanie Perniciaro; Matthias Imöhl
Journal:  BMC Infect Dis       Date:  2015-05-05       Impact factor: 3.090

View more
  2 in total

1.  Molecular characterization and epidemiology of Streptococcus pneumoniae serotype 8 in Denmark.

Authors:  Camilla Bülow Hansen; Kurt Fuursted; Palle Valentiner-Branth; Tine Dalby; Charlotte Sværke Jørgensen; H-C Slotved
Journal:  BMC Infect Dis       Date:  2021-05-05       Impact factor: 3.090

2.  Multi-Locus Sequence Typing and Drug Resistance Analysis of Swine Origin Escherichia coli in Shandong of China and Its Potential Risk on Public Health.

Authors:  Wei Wang; Lanping Yu; Wenwen Hao; Fusen Zhang; Meijie Jiang; Shuping Zhao; Fangkun Wang
Journal:  Front Public Health       Date:  2021-12-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.